Terms: = Pancreatic cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Diagnosis
56 results:
1. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract] [Full Text] [Related]
2. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract] [Full Text] [Related]
3. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract] [Full Text] [Related]
4. AUM302, a novel triple kinase PIM/PI3K/mtor inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
[TBL] [Abstract] [Full Text] [Related]
5. VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAmtor2-mediated mtor activation.
Xu J; Quan G; Huang W; Jiang J
Cell Commun Signal; 2023 Aug; 21(1):223. PubMed ID: 37626304
[TBL] [Abstract] [Full Text] [Related]
6. Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups.
Mattiolo P; Gkountakos A; Centonze G; Bevere M; Piccoli P; Ammendola S; Pedrazzani C; Landoni L; Cingarlini S; Milella M; Milione M; Luchini C; Scarpa A; Simbolo M
Pathol Res Pract; 2023 Aug; 248():154674. PubMed ID: 37454491
[TBL] [Abstract] [Full Text] [Related]
7. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
Fazio N; La Salvia A
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
[TBL] [Abstract] [Full Text] [Related]
8. Effect of STK3 on proliferation and apoptosis of pancreatic cancer cells via PI3K/AKT/mtor pathway.
Chen J; Liu F; Wu J; Yang Y; He J; Wu F; Yang K; Li J; Jiang Z; Jiang Z
Cell Signal; 2023 Jun; 106():110642. PubMed ID: 36871796
[TBL] [Abstract] [Full Text] [Related]
9. The roles and mechanisms of circular RNAs related to mtor in cancers.
Cao C; Wang Y; Wu X; Li Z; Guo J; Sun W
J Clin Lab Anal; 2022 Dec; 36(12):e24783. PubMed ID: 36426933
[TBL] [Abstract] [Full Text] [Related]
10. Tuberous sclerosis complex-associated nonfunctional pancreatic neuroendocrine tumors: Management and surgical outcomes.
Evans LM; Geenen KR; O'Shea A; Hedgire SS; Ferrone CR; Thiele EA
Am J Med Genet A; 2022 Sep; 188(9):2666-2671. PubMed ID: 35612824
[TBL] [Abstract] [Full Text] [Related]
11. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract] [Full Text] [Related]
12. pancreatic cancer treatment with targeted therapies: are we there yet?
Ngozi Nwaefulu O; Rao Sagineedu S; Kaisarul Islam M; Stanslas J
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):367-381. PubMed ID: 35113412
[TBL] [Abstract] [Full Text] [Related]
13. Moving Towards Dawn: KRas Signaling and Treatment in pancreatic Ductal Adenocarcinoma.
Rajpurohit T; Bhattacharya S
Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
[TBL] [Abstract] [Full Text] [Related]
14. Pitfalls in the diagnosis of yolk sac tumor: Lessons from a clinical trial.
Yang A; Patterson A; Pavlock T; Chen KS; Gagan J; Hatley ME; Frazier AL; Amatruda JF; Laetsch TW; Rakheja D
Pediatr Blood Cancer; 2022 Feb; 69(2):e29451. PubMed ID: 34866303
[TBL] [Abstract] [Full Text] [Related]
15. MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer.
Sarwar A; Wang B; Su Q; Zhang Y
Biochem Pharmacol; 2021 Jul; 189():114357. PubMed ID: 33279497
[TBL] [Abstract] [Full Text] [Related]
16. Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers.
Alizadeh A; Jebelli A; Baradaran B; Amini M; Oroojalian F; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Gene; 2021 Feb; 769():145224. PubMed ID: 33059027
[TBL] [Abstract] [Full Text] [Related]
17. C24-Ceramide Drives Gallbladder cancer Progression Through Directly Targeting Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation.
Zhang Y; Wang H; Chen T; Wang H; Liang X; Zhang Y; Duan J; Qian S; Qiao K; Zhang L; Liu Y; Wang J
Hepatology; 2021 Feb; 73(2):692-712. PubMed ID: 32374916
[TBL] [Abstract] [Full Text] [Related]
18. The (pro)renin receptor: a novel biomarker and potential therapeutic target for various cancers.
Wang J; Nishiyama A; Matsuyama M; Wang Z; Yuan Y
Cell Commun Signal; 2020 Mar; 18(1):39. PubMed ID: 32143717
[TBL] [Abstract] [Full Text] [Related]
19. Clinical significance and oncogene function of long noncoding RNA HAGLROS overexpression in ovarian cancer.
Yang M; Zhai Z; Zhang Y; Wang Y
Arch Gynecol Obstet; 2019 Sep; 300(3):703-710. PubMed ID: 31197441
[TBL] [Abstract] [Full Text] [Related]
20. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mtor inhibitor.
Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
[TBL] [Abstract] [Full Text] [Related]
[Next]
